Michael J Frank

US Patent:

51590638, Oct 27, 1992

Filed:

Feb 2, 1989

Appl. No.:

7/305458

Inventors:

Carl H. Hammer - Gaithersburg MD
Ruth M. Jacobs - Bethesda MD
Michael M. Frank - Bethesda MD

Assignee:

The United States of America as represented by the Department of Health
and Human Services - Washington DC

International Classification:

C07K 1514
A61K 3516

US Classification:

530380

Abstract:

A substantially pure, single chain plasma protein of approximately 120 kDa having an N-terminal amino acid sequence EKNGIDIYSLTD, and a mixture of protein fragments having vasodilatory activity which fragments are generated by activated Kallikrein cleavage of the 120 kDa protein.

US Patent:

50305786, Jul 9, 1991

Filed:

Jul 10, 1989

Appl. No.:

7/377334

Inventors:

Yannick M. Pilatte - Rockville MD
Carl H. Hammer - Gaithersburg MD
Michael M. Frank - Bethesda MD
Louis F. Fries - Ellicott City MD

Assignee:

The United States of America as represented by the Secretary of the
Department of Health and Human Services - Washington DC

International Classification:

G01N 30100

US Classification:

436 86

Abstract:

C1-inhibitor (C1-Inh), the major regulatory protein of the classical pathway of complement activation, can be purified in a new, simplied three step procedure which includes PEG fractionation, jacalin-agarose chromatography and hydrophobic interaction chromatography on phenyl-Sepharose which takes advantage of the marked hydrophilicity of the inhibitor. This procedure has major advantages over those which have been the most frequently used. This method may be highly adaptable to bulk purification for clinical use or for performing analytical or functional studies on genetically or pathologically altered C1-Inh from clinical specimens.

US Patent:

48206350, Apr 11, 1989

Filed:

Jul 31, 1987

Appl. No.:

7/079925

Inventors:

Martin E. Sanders - Gaithersburg MD
Keith A. Joiner - Rockville MD
Michael M. Frank - Bethesda MD
Carl H. Hammer - Gaithersburg MD

Assignee:

The United States of America as represented by the Department of Health
and Human Services - Washington DC

International Classification:

G01N 3353

US Classification:

435 7

Abstract:

A kit for assaying the activation of terminal complement cascade is disclosed. The kit includes a plurality of containers which contain a first antibody having a specificity for poly C9 neoantigen. The containers further have a second antibody which is different from the first antibody and has a specificity for a constituent of terminal complement cascade. A third antibody is optionally present which recognizes the second antibody. The kit also includes a substrate splitting enzyme, a substrate for the enzyme which produces a color reaction when split, and a SCb-9 standard microtiter plate. Pipettes and instructions for performing the assay are also included.

US Patent:

51716631, Dec 15, 1992

Filed:

Jun 14, 1989

Appl. No.:

7/365772

Inventors:

Milan Basta - Rockville MD
Carl H. Hammer - Gaithersburg MD
Michael M. Frank - Bethesda MD

Assignee:

The United Stated of America as represented by the Secretary of the
Department of Health and Human Services - Washington DC

International Classification:

G01N 3353

US Classification:

435 71

Abstract:

Monoclonal antibodies against complement regulatory protein sgp 120 are provided.

US Patent:

47228903, Feb 2, 1988

Filed:

Aug 27, 1985

Appl. No.:

6/769684

Inventors:

Martin E. Sanders - Gaithersburg MD
Keith A. Joiner - Rockville MD
Michael M. Frank - Bethesda MD
Carl H. Hammer - Gaithersburg MD

Assignee:

The United States of America as represented by the Department of Health
and Human Services - Washington DC

International Classification:

G01N 5300

US Classification:

435 7

Abstract:

The present invention discloses an enzyme-linked immunosorbent assay (ELISA) to quantitate fluid phase terminal complement activation. Upon activation to form C5b-9, terminal complement components express neoantigens not present in the unassembled individual components. Rabbit antiserum to polymerized C9 was rendered specific for C9 neoantigenic determinants by serial immunosorbtion with human serum, human C9, and other terminal complement components bound to Sepharose. Using the IgG from this antiserum, a sandwich ELISA was devised to bind SC5b-9 from solution onto polystyrene plates. The ELISA plates were developed with the use of goat antiserum to native C9 epitopes followed by a swine anti-goat IgG alkaline phosphatase conjugate. Quantitation of SC5b-9 in solution was performed by comparing sample OD to a standard curve generated with human SC5b-9 that was purified from zymosan-activated serum. The assay is sensitive to as little as 100 ng of SC5b-9/ml and is useful for screening plasma, serum, cerebrospinal fluid, or other biological fluids for the presence of terminal complement cascade activation.